The role of multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy in active surveillance for low-risk prostate cancer: A systematic review
| Autor: | Muhammad Ahmad Al-Ghamdi, Ali Salem Autwdi, Abdulrahim Mohammed Alamri, Sultan Zaher Alshehri, Saeed Ahmed Al-Ghamdi, Nazal Ahmed Almsaoud, Muath Mohammed Almurayyi, Abdulaziz Mohammed Alqahtani, Omar Safar Alshahrani, Mohammed Mesadef Zogan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Review Article Active surveillance Disease 03 medical and health sciences Prostate cancer 0302 clinical medicine Biopsy medicine Radiation treatment planning Grading (tumors) Multiparametric Magnetic Resonance Imaging medicine.diagnostic_test business.industry Disease progression Magnetic resonance imaging General Medicine medicine.disease 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Surgery Radiology business MRI MRGB |
| Zdroj: | Annals of Medicine and Surgery |
| ISSN: | 2049-0801 |
| Popis: | The performance of multiparametric magnetic resonance imaging (mpMRI) and subsequent biopsy in monitoring prostate cancer in men on active surveillance (AS) have not been defined clearly. In this systematic review, we aimed to review current literature about the usage of MRI examination in men with low-risk prostate cancer during active surveillance. For that, we searched seven databases to include all studies reporting magnetic resonance imaging in the AS of low-risk prostate cancer. We finally included 11 studies with 1237 patients included. Our results showed an adequate sensitivity and specificity of both modalities to detect disease progression; including disease upgrading and upstaging. However, the performance in the prediction of unfavorable disease was inferior to the detection of upgrading and upstaging. In terms of MRGB, the previous literature agreed on the superiority of using a combination of different biopsy schemes to get a better progression section. Noteworthy, mp-MRI and MRGB had a good predictive value limited to the first year, with TRUSGB showing a superior role in detecting patients with a GS ≥ 7, after that. In conclusion, both of mpMRI and MRGB have shown an adequate performance on assessing disease progression in the AS of low-risk prostate cancer patients. They can be used for disease staging and grading for successful treatment planning. HIGHLIGHTS • In comparison to the literature, few papers discuss the benefit of MRI screening in low-risk prostate cancer groups. • Biopsy is considered more invasive than MRI, thus reducing the burden of such methods on the patients. • PSA values can be misinterpreted especially that it can rise in other diseases such as Benign Prostatic Hyperplasia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|